Osteosarcoma. Specific tumor management and results.
The survival rate of patients with osteogenic sarcoma has greatly improved with the institution of a multidisciplinary approach that combines multi-agent chemotherapy and limb-sparing surgery. Presently, 80% of those patients who do not have distant metastases at presentation will become long-term survivors, compared to 20% prior to 1970. For patients with metastases at diagnosis, or who develop metastases after initiation of treatment, long-term survival is also possible if all primary and metastatic disease is removed. The data presented in this article supports aggressive resection of pulmonary metastases in osteogenic sarcoma patients.
La Quaglia
M P
MP
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms; D003131:Combined Modality Therapy; D004724:Endoscopy; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000601:surgery; D012516:Osteosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D011013:Pneumonectomy; D015996:Survival Rate; D013906:Thoracoscopy; D013908:Thoracotomy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome